Featured Video
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
15:31 MIN
- CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
Our Experts
Claudia Sommer, MD
University of Würzburg, Würzburg, Germany
Claudia Sommer, MD
University of Würzburg, Würzburg, Germany
- MMN
Claudia Sommer is a Professor of Neurology at the University of W├╝rzburg, Germany.
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
- CIDP
Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina.
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
- CIDP
Peter Van den Bergh is Professor of Neurology at the Université Catholique de Louvain and Director of the Neuromuscular Centre of Reference of the Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Carol L. Koski, MD
GBS/CIDP Foundation International
Carol L. Koski, MD
GBS/CIDP Foundation International
- CIDP
- GBS
Dr. Koski is a retired Professor of Neurology from the University of Maryland School of Medicine and is currently a Director of the GBS/CIDP Foundation International.
Back to Top